[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercytokinemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercytokinemia":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100453964",false,"NCT05191381","Immune Modulation by Exosomes in COVID-19","Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19","IMECOV19","Inclusion Criteria:\n\n* Critically ill COVID-19 patients with lung dysfunction\n* COVID-19 WHO severity degree \\>= 4, ARDS (WHO Definition 13 March 2020)\n* Body weight \\> 50 kg\n* Informed consent\n\nExclusion Criteria:\n\n* Pregnant or breast feeding women",true,"ALL","18 Years","90 Years",{"count":21,"type":22},40,"ESTIMATED","12 Months","OBSERVATIONAL","Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.",[27,28,29,30],"COVID-19","Critical Illness","Hypercytokinemia","Lung Fibrosis",[27,32,29,33,34,35,36,37],"Critical illness","Exosomes","Mesenchymal stem cells","Tissue reconstitution","Immune modulation","Sepsis","RECRUITING","2024-01-16",{"date":41,"type":42},"2024-01-17","ACTUAL",{"date":44,"type":42},"2021-12-22",{"date":46,"type":22},"2026-12-31",{"name":48,"class":49},"University of Ulm","OTHER",""]